Adapting for the future of oncology trialsAdvanced analytical solutions provider Cytel is at the forefront of rapid changes in oncology R&D. We spoke with Share XAdapting for the future of oncology trialshttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/cytel-future-adaptive-trials-cancer/
Moving from autologous to allogeneic ACT paradigmsWe have come so far in a relatively short time with Adoptive Cellular Transfer (ACT). The two marketed Share XMoving from autologous to allogeneic ACT paradigmshttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/icon-allogeneic-adoptive-cellular-transfer/
Did cancer clinical trials stay on track at ASCO 2019?Chicago is recovering after 40,000 oncologists and cancer experts descended on the city for this year’s ASCO conference. Share XDid cancer clinical trials stay on track at ASCO 2019?https://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/kantar-cancer-clinical-trials/
Why pharma needs honest patient dialogueAstellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug pricing, collaboration and improving the Share XWhy pharma needs honest patient dialoguehttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/astellas-pharma-percival-barretto-ko/
Can in vivo imaging deliver the full potential of immunotherapy?In the quest to control cancer we now face the challenge of translating our increasing insights into the Share XCan in vivo imaging deliver the full potential of immunotherapy?https://pharmaphorum.com/views-analysis-oncology/can-in-vivo-imaging-deliver-the-full-potential-of-immunotherapy/
As cancer treatments evolve, so must investment mechanismsLast month’s American Society of Clinical Oncology (ASCO) meeting kicked off with a presentation from Professor Ruth Plummer, Share XAs cancer treatments evolve, so must investment mechanismshttps://pharmaphorum.com/views-analysis-oncology/as-cancer-treatments-evolve-so-must-investment-mechanisms/
ASCO 2019 round-upWith the American Society of Clinical Oncology (ASCO) conference over for another year, Richard Staines presents a round-up Share XASCO 2019 round-uphttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-round-up/
ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialKantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last Share XASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/kantar-macrogenics-phase-3-sophia-trial/
ASCO 2019 – phase I data generates hope for the futureSometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. Share XASCO 2019 – phase I data generates hope for the futurehttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/amgen-kras-amg510-phase-i-data/
